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Pulmonary fibrosis is the consequence of a variety of diseases with no satisfying treatment 
option. Therapy-induced fibrosis also limits the efficacy of chemotherapy and radiotherapy 
in numerous cancers. Here, we studied the potential of platelet-derived growth factor (PDGF) 
receptor tyrosine kinase inhibitors (RTKIs) to attenuate radiation-induced pulmonary fibrosis. 
Thoraces of C57BL/6 mice were irradiated (20 Gy), and mice were treated with three distinct 
PDGF RTKIs (SU9518, SU11657, or Imatinib). Irradiation was found to induce severe lung 
fibrosis resulting in dramatically reduced mouse survival. Treatment with PDGF RTKIs 
markedly attenuated the development of pulmonary fibrosis in excellent correlation with 
clinical, histological, and computed tomography results. Importantly, RTKIs also prolonged 
the life span of irradiated mice. We found that radiation up-regulated expression of PDGF 
(A–D) isoforms leading to phosphorylation of PDGF receptor, which was strongly inhibited 
by RTKIs. Our findings suggest a pivotal role of PDGF signaling in the pathogenesis of 
pulmonary fibrosis and indicate that inhibition of fibrogenesis, rather than inflammation, 
is critical to antifibrotic treatment. This study points the way to a potential new approach 
for treating idiopathic or therapy-related forms of lung fibrosis.
 
Pulmonary fibrosis comprises a group of inter-
stitial disorders of the lung parenchyma that
develop as a consequence of multiple causes,
including radiotherapy and chemotherapy for
lung neoplasms (1, 2). The pathophysiologic
events induced by radiation have striking simi-
larities to those that occur after other types of
lung injury, such as surgery, chemotherapy,
and idiopathic pulmonary fibrosis (IPF; refer-
ence 3). IPF is the most common form of lung
fibrosis with a prevalence of 16–18 cases per
100,000 (4, 5). Clinically, IPF is characterized
by interstitial infiltrates, progressive dyspnea,
and worsening of pulmonary function that may
lead to death from respiratory failure (1, 6, 7).
Despite the medical need, there has been re-
markably little progress in the development of
effective therapeutic strategies (1, 6–9).
It has been proposed that fibrogenesis is
not a unique pathologic process but rather, is
due to an excess of the same biologic events
involved in normal tissue repair (10). Persistent
and exaggerated wound healing ultimately
leads to an excess of fibroblast replication and
matrix deposition (1, 6–9). Evidence for the
importance of platelet-derived growth factor
(PDGF) signaling in the fibrotic process is
provided by reports showing that a number of
fibrogenic mediators such as TGF-
 
 
 
, IL-1,
TNF-
 
 
 
, bFGF, and thrombin exhibit PDGF-
dependent profibrotic activities (6, 11–14).
From the involvement of PDGF in the fibrotic
process, it has been suggested that the PDGF–
PDGFR system might be a promising target
for treating fibrotic disease (15). The PDGF
family consists of a family of disulfide-bonded
homodimers or heterodimers of four possible
subunits (PDGF-A, PDGF-B, PDGF-C, and
PDGF-D) that act on cells by binding to ho-
modimers or heterodimers of the two PDGF re-
ceptor proteins (PDGFR-
 
 
 
 and PDGFR-
 
 
 
) and
activating their receptor tyrosine kinase activity
(for a review see reference 16). An ideal animal
model for IPF does not exist, but bleomycin-
and radiation-induced lung fibrosis models have
been used to study lung fibrosis (3, 8, 17–24).
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In this study, we investigate the role of the PDGF–
PDGFR system in the development of lung fibrosis in a ra-
diation-induced fibrosis model using C57BL/6 mice. To
evaluate a potential antifibrotic therapy, we also tested the
hypothesis whether treatment with PDGF receptor tyrosine
kinase inhibitors (RTKIs) might be an effective strategy to
attenuate fibrogenesis, even if administered after radiation
injury. We used three different RTKIs (SU9518, SU11657,
and Imatinib/Gleevec) that overlap in their ability to inhibit
both PDGFR-
 
 
 
 and PDGFR-
 
 
 
. The encouraging results
from this study provide a rationale for clinical trials based on
available PDGF RTKIs in patients with pulmonary fibrosis.
 
RESULTS
PDGF signaling in vitro
 
Because radiation causes tumor cells to express pro-angio-
genic factors (25) and is clinically known to cause fibrosis,
we asked if radiation might also induce profibrotic factors
and which cells other than macrophages (26–28) might con-
tribute to radiation-induced fibrosis. To this end, we used a
coculture model of human fibroblasts in conjunction with
either human endothelial cells (human umbilical vein endo-
thelial cells [HUVECs] and human lung microvascular en-
dothelial cells [HLMVECs]) or a human lung cancer cell line
(A549). Selective radiation of either endothelial cells or
A549 cells in the coculture immediately before adding tran-
swells with the fibroblasts induced fibroblast proliferation by
2.4 
 
  
 
0.5- and 1.7 
 
  
 
0.3-fold, respectively. If SU9518 was
added in the fibroblast compartment, radiation-induced fi-
broblast proliferation was inhibited by 65 
 
  
 
8% (A549) and
46 
 
  
 
7% (HUVEC), respectively (Fig. 1 A). Similar data
were obtained using irradiated HLMVEC instead of HU-
VEC for paracrine stimulation (not depicted).
Immunoprecipitation (IP) western analysis of the fibro-
blast cells revealed that irradiation of the endothelial cells or
A549 cells induced phosphorylation of PDGFR in fibroblasts
at 6 and 72 h after irradiation, confirming the role of PDGF
signaling in intercell communication. This paracrine activa-
tion of PDGFR was inhibited by the addition of SU9518 to
the fibroblast compartment (Fig. 1 B). To confirm that en-
dothelial and A549 cells have up-regulated PDGF after radia-
tion and to determine which isoforms are released, we mea-
sured the expression levels of all four PDGF isoforms (A–D)
using real-time quantitative RT-PCR (Fig. 1 C). All PDGF
isoforms were significantly up-regulated after 10 Gy radiation
in HLMVEC (P 
 
  
 
0.01) and A549 cells (P 
 
  
 
0.02), which
persisted up to 72 h after irradiation. Although the PDGF-B
(greater than fivefold), PDGF-C (greater than sixfold), and
PDGF-D (greater than fourfold) were the predominant radia-
tion-induced PDGF isoforms in HLMVEC, PDGF-A
(greater than twofold) and PDGF-B (greater than fivefold)
were more strongly up-regulated in irradiated A549 cells. Be-
cause fibroblast activation is thought to be a critical event in
fibrogenesis, these in vitro results suggested that inhibition of
PDGF signaling might be a way to attenuate this process.
 
Radiation-induced lung fibrosis
 
Exposure of normal lung tissue to irradiation has two well-
recognized adverse effects: acute/subacute pneumonitis and
fibrosis as a long-term sequela (2, 3, 19, 22–24, 29). To
translate the coculture results in vivo, we conducted an ex-
periment with a total of 312 C57BL/6 mice randomized
into 8 groups of 30–56 animals. Six groups were irradiated
with either 20 Gy or 40 Gy and were administered the vehi-
cle or the PDGFR kinase inhibitor, SU9518, either 1 d be-
fore or 3 d after irradiation. In both arms, SU9518 was ad-
ministered s.c. twice weekly throughout the observation
period (up to 26 wk after irradiation). The two nonirradiated
groups received either vehicle only or SU9518. To test the
pharmacokinetics of SU9518, plasma levels were determined
after a single s.c. dose (100 mg/kg) was administered to
C57BL/6 mice. The plasma levels of SU9518 rose to a peak
within 2 h of administration and decayed slowly over the
next several days with a half-life of 
 
 
 
73.6 h (Fig. 2 A). This
was in agreement with our previous results showing that
SU9518 is a potent inhibitor of both PDGFR
 
  
 
and PDG-
FR
 
  
 
tyrosine kinases, and that it had a long duration of
Figure 1. Radiation-induced paracrine activation of fibroblasts in 
a coculture system. (A) Fibroblast proliferation induced by exposure to 
coculture medium (Control) or by prior 10 Gy irradiation of HUVECs or 
A549 cells in the absence (RT) or presence of SU9518 (SU9518 RT) in the 
fibroblast medium. Mean   SD. *, P   0.05. (B) Phosphorylation status 
(anti-phosphorylated tyrosine antibody, anti-pY) of PDGFR  in quiescent 
fibroblasts, fibroblasts exposed to medium from 10 Gy irradiated endothe-
lial cells (6 and 72 h after radiation, RT), or with additional exposure to 
PDGF RTKI, SU9518 (RT SU). Equal loading of lanes was demonstrated 
with anti-PDGFR . (C) Real-time quantitative RT-PCR of PDGF-A, PDGF-B, 
PDGF-C, and PDGF-D isoforms at 6, 12, 24, 48, and 72 h after 10 Gy irradi-
ation of HLMVECs and A549 cells. Data are means   SD from at least 
three independent measurements and show relative expression levels 
compared with the nonirradiated control cells at each time point. 
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plasma exposure when administered s.c. to rats (30). To con-
firm the presence of an effective therapeutic dose using twice
weekly administration, SU9518 plasma concentrations were
measured every 4 wk (3 d after the last s.c. injection) during
the entire therapy period. The SU9518 plasma concentra-
tion was remarkably constant with values varying between
710 
 
  
 
45 and 777 
 
  
 
160.03 ng/ml.
 
Antifibrotic therapy by PDGF inhibition prolongs 
mouse survival
 
We found that a single dose of thoracic irradiation (20 Gy) led
to lung fibrosis and reduced animal survival, with a median
survival of 22 wk versus untreated control mice that stayed
alive for 
 
 
 
1 yr (P 
 
  
 
0.0001). Challenging mice with the very
high single radiation dose of 40 Gy resulted in a dramatic re-
duction of the median survival down to 
 
 
 
1 wk after irradia-
tion (Fig. 2 B). SU9518 treatment prolonged median survival
by 10 wk (20 Gy: from 22 to 32 wk, P 
 
  
 
0.006) and 5 wk
(40 Gy: from 1 to 6 wk, P 
 
  
 
0.04) if administration started
3 d after radiation. If SU9518 administration started before
radiation injury, life span was also prolonged but was not sta-
tistically significant (20 Gy: P 
 
  
 
0.15; 40 Gy: P 
 
  
 
0.22).
SU9518 treatment also attenuated radiation-related clini-
cal adverse effects such as weight loss (P 
 
  
 
0.02, at all time
points after week 14). Similar beneficial effects of SU9518
treatment were observed in other clinical parameters that
were monitored weekly during the entire observation pe-
riod, including animal behavior (worse after irradiation, im-
proved by SU9518), tachypnea, and heart rate (both higher
after irradiation, reduced by SU9518).
Because the fibrosis process appeared to be more relevant
to survival of mice irradiated with 20 Gy and less important
for the animals treated with the very high dose of 40 Gy, we
focused on 20 Gy to illustrate the radiological and patholog-
ical changes in subsequent experiments.
 
Confirmation using PDGFR inhibitors SU11657 and Imatinib
 
The above in vitro and in vivo data suggested that the effects
resulted from inhibition of PDGFR in proliferating fibro-
blasts. However, because kinase inhibitors never exhibit ex-
quisite selectivity, the possibility that the effects might be
mediated by inhibition of other kinases cannot be com-
pletely excluded. Therefore, key experiments were repeated
with Imatinib (Gleevec) and SU11657, two other PDGF
RTKIs that are expected to have different kinase selectivity
profiles. Because of the poor pharmacokinetic properties of
Gleevec in mice (31) and the long duration of dosing, we
chose oral administration with the compound formulated in
the animal diet. As with the most effective regimen using
SU9518 from the experiments described above, anti-PDGF
treatment started 3 d after 20 Gy thoracic irradiation. Fig. 2 C
shows that both SU11657 and Imatinib treatment signifi-
cantly prolonged the survival of irradiated mice (P 
 
  
 
0.01).
The median survival increased in this independent experi-
ment markedly from 19 to 
 
 
 
30 wk. We did not observe a
Figure 2. Inhibition of PDGF signaling prolongs survival of irradiated 
mice. (A) Pharmacokinetic analysis of plasma SU9518 (structure shown as 
inset) concentration after a single dose of 100 mg/kg administered s.c. 
to C57BL/6 mice. Tmax   2 h; Cmax   706 ng/ml; T1/2   73.6 h. (B) Kaplan-
Meier analysis of mouse survival after thoracic irradiation and SU9518 
treatment. Death was considered complete (cause specific due to radiation) 
in all cases except those of planned euthanasia for histological assessment, 
which were considered as censored. Radiation (20 or 40 Gy) reduced 
survival (P   0.001 vs. the control [100  l carboxymethylcellulose twice 
weekly]; log-rank). SU9518 had no influence on survival of unirradiated 
mice (P   0.95 vs. the control). The difference between prevention 
(SU9518 started 1 d before irradiation) and intervention (SU9518 started 3 d 
after irradiation) was significant for the 20 Gy group but not for the 40 Gy 
group (P   0.035/20 Gy; P   0.41/40 Gy). SU9518 prevention in both the 
20 and 40 Gy group tended to increase survival versus radiation alone, but 
was not statistically significant (P   0.15/20 Gy; P   0.22/40 Gy). If SU9518 
administration was started 3 d after 20 Gy irradiation (intervention, 
20Gy SU9518, 40Gy SU9518), mouse survival increased markedly 
versus radiation alone (P   0.006/20 Gy; P   0.04/40 Gy). (C) Kaplan-Meier 
analysis of mouse survival from independent confirmation experiments 
using two other PDGF RTKIs (Imatinib and SU11657) with administra-
tion starting 3 d after thoracic irradiation (20 Gy, intervention). Both 
Imatinib and SU11657 significantly increased survival of irradiated mice 
(P   0.01). 
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statistically significant difference in animal survival between
Imatinib and SU11657 therapy (P 
 
  
 
0.5). Furthermore, as
with the SU9518 treatment reported above, SU11657 and
Imatinib improved all clinical parameters (weight, heart rate,
and breathing frequency) in 20 Gy irradiated mice that were
monitored weekly over the 26-wk observation period.
 
In vivo detection of PDGF signaling
 
PDGF-B, PDGFR-
 
 
 
, and activated PDGFR-
 
  
 
(phosphory-
lated) were analyzed in mouse lung specimens using immu-
nohistochemistry and IP Western blotting (IP-western). We
found that radiation-induced persistent expression of PDGF-B
and phosphorylation of the PDGFR (Fig. 3 A) in lungs for
Figure 3. Constitutive activation of PDGF signaling in mouse lungs. 
(A) Immunohistochemical analysis demonstrates strong induction of 
PDGF-B and PDGFR-  expression in lung sections 4 wk after 20 Gy total 
thoracic irradiation (RT). Phosphorylation of PDGFR-  (p-PDGFR- ) was 
also enhanced in irradiated (RT) versus control mice. Treatment with 
SU9518 (RT SU) significantly reduced phosphorylation of PDGFR- . Bar, 
100  m. (B) 2, 4, and 20 wk after 20 Gy irradiation (RT) and administration 
of SU9518 (SU RT and RT SU), mice were killed and the lungs were har-
vested for protein isolation. The amount of phosphorylated PDGFR-  
(anti-pY) was determined by immunoblotting. Equal loading of lanes was 
demonstrated with anti-PDGFR . (C) Real-time quantitative RT-PCR of 
PDGF-A, PDGF-B, PDGF-C, and PDGF-D isoforms detected in RNA from 
mouse lung after SU9518 treatment, 20 Gy thoracic irradiation (RT), and 
SU9518 administered after lung radiation (RT SU9518). In irradiated lung 
specimen, significant up-regulation of all four PDGF isoforms are shown 
at 2 and 4 wk after irradiation (*, P   0.01) as well as for PDGF-A, PDGF-B, 
and PDGF–C isoforms at 20 wk (§, P   0.001). The expression of the PDGF-A, 
PDGF-B, and PDGF-C isoforms is significantly impaired at 20 wk after irra-
diation in SU9518-treated mice (#, P   0.02), whereas the PDGF expres-
sion at earlier time points is not markedly affected by PDGF RTK. This data 
underscore that the inhibition of fibrosis is the principal target for PDGF 
RTKIs. Bars are means   SD from three independent measurements and 
show relative expression levels compared with the nonirradiated lung 
tissue at 2, 4, and 20 wk after radiation. 
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most of the time points analyzed during the 26-wk observa-
tion period. This radiation-induced PDGFR phosphoryla-
tion was reduced by RTKI treatment. The activation of
PDGFR
 
  
 
was confirmed by IP-western, which demon-
strated radiation-induced phosphorylation of PDGFR. IP-
western also demonstrated that radiation-induced phosphor-
ylation of PDGFR could be inhibited by SU9518 at various
time points e.g., at 2, 4, and 20 wk after radiation (Fig. 3 B).
This attenuation of PDGFR phosphorylation was seen in the
group where SU9518 treatment started before irradiation
(prevention, SU9518
 
 
 
RT) as well as in the group where
SU9518 treatment started after irradiation (intervention,
RT
 
 
 
SU9518). In addition, real-time quantitative RT-PCR
revealed significant up-regulation of all four PDGF isoforms
in irradiated lung specimen at 2 and 4 wk after irradiation
(P 
 
  
 
0.01) as well as for PDGF-A, PDGF-B, and PDGF-C
isoforms at 20 wk (P 
 
  
 
0.001). The PDGF-B and PDGF-C
RNA levels were elevated stronger at the early time points
(2 and 4 wk), whereas PDGF-A was the predominant iso-
form at 20 wk. Interestingly, the PDGF-A, PDGF-B, and
PDGF-D isoforms appeared to be slightly (between 1- and
1.2-fold) elevated after the PDGF RTK inhibitor SU9518
(P 
 
  
 
0.05). A similar up-regulation of ligands has been
shown for other RTKIs in human trials using VEGFR TKIs.
In contrast, the fibrosis-related expression of the PDGF-A,
PDGF-B, and PDGFC isoforms was significantly impaired at
20 wk after irradiation in SU9518-treated mice (P 
 
  
 
0.02).
In accordance with the late onset of fibrosis development
that is attenuated by PDGF RTKI, PDGF expression is not
markedly affected by SU9518 at earlier time points. Again,
these data underscore that the inhibition of fibrosis is the
principal target of PDGF RTKI.
 
High resolution computed tomography (CT) of mouse lungs
 
To obtain an independent qualitative and quantitative mea-
sure of lung fibrosis that could be repeated in the same animal
Figure 4. High resolution CT as a noninvasive tool for qualitative 
and quantitative longitudinal monitoring of pulmonary fibrosis 
progression in mice. Treatment with SU9518 started either 1 d before 
20 Gy irradiation (SU9518 RT) or 3 d after irradiation (RT SU9518). 
(A) Representative CT scans showing progression of pulmonary fibrosis in 
mice after 20 Gy whole thorax irradiation (RT) and treatment with SU9518 
treatment starting 3 d after RT. Fibrosis (black arrows) is characterized by 
diffuse bilateral areas of “ground-glass” attenuation and intralobular 
reticular opacities. (B, C, and D) Quantitative lung density values derived 
from CT scans. The same 10 randomly chosen mice in each treatment 
group were examined in a longitudinal study by CT every 2 wk. Five regions 
of interest were randomly selected in the lungs, and the lung density (in HU) 
was determined for each region of interest. The time course in B shows 
that intervention and prevention schedule were both effective in attenu-
ating radiation-induced lung density, and SU9518 intervention (RT SU9518) 
was slightly more effective than SU9518 prevention after week 20 (P   
0.05). Bars are mean   SE. *, P   0.001 versus the control; #, P   0.01 
versus RT (B and D). (E) Independent confirmatory experiment using 
Imatinib and SU11657. Inhibitor administration started on day 3 after 
20 Gy thoracic irradiation (20 Gy). Both compounds are very effective in 
attenuating radiation-induced enhancement of lung density. Bars show 
lung density derived from CT scans (mean   SE). *, P   0.01 versus control; 
#, P   0.01 versus RT.ATTENUATION OF LUNG FIBROSIS | Abdollahi et al. 930
over time, we used CT. After week 16, typical CT features of
lung fibrosis were observed in the 20 Gy group, including ir-
regular septal thickening, patchy peripheral reticular abnor-
malities with intralobular linear opacities, and subpleural
honeycombing (Fig. 4 A). The extent of fibrotic disease pro-
gression in CT correlated well with histology and clinical im-
pairment. SU9518 treatment markedly reduced the radio-
logical/morphological signs of fibrosis in both the prevention
and intervention groups (P   0.01). In addition to morpho-
logic assessment, CT enabled quantitation of fibrosis by assess-
ment of lung density (quantified in Hounsfield units [HU]).
Lung density dramatically increased during weeks 12–24 after
radiotherapy (Fig. 4 B). SU9518 in both the intervention and
prevention arms strongly inhibited this increase by  50%
(Fig. 4, C and D; P   0.001). The intervention arm appeared
to be slightly more effective than the prevention arm after
week 20 (Fig. 4 B; P   0.05). In the independent confirma-
tion experiments using Imatinib and SU11657 treatments,
lung densities were also dramatically reduced in irradiated
mice by  50% by both compounds (Fig. 4 E; P   0.05).
Histological assessment of lung fibrosis
To better understand the pathogenesis of the radiation-
induced lung fibrosis process and to evaluate the modulation
by PDGF RTKI, mice were selected for analysis of leuko-
cyte infiltration, edema, and collagen deposition with associ-
ated thickening of the alveolar septum.
We observed a biphasic radiation response, initially con-
sisting of acute and subacute pneumonitis (Fig. 5 and Figs.
S1–S3, available at http://www.jem.org/cgi/content/full/
jem.20041393/DC1), which was followed by the onset of
fibrogenesis. The characteristic histologic findings in the
pneumonitis phase of the radiation response were prominent
inflammatory cell infiltrates in the alveoli and lung intersti-
tium with simultaneous interstitial edema (Fig. 5, C and E).
Both parameters exhibited similar kinetics in the acute phase,
reaching their maximum  72 h after radiation injury. After
the acute radiation response, both leukocyte count and septal
edema spontaneously subsided within a few days. SU9518
administration starting 1 d before irradiation (prevention, but
then given continuously for the observation period) reduced
the edema by  40     10% at 24 h (P    0.02). When
SU9518 administration started 3 d after radiation (interven-
tion, but then given continuously for the observation pe-
riod) a significant reduction of edema (by 50   15%) was
first detected at 1 wk after radiation (P   0.02). Interest-
ingly, SU9518 treatment did not significantly decrease this
first, radiation-induced acute leukocyte peak (P   0.2).
In irradiated mice, the later fibrogenesis phase was ac-
companied by a strong second onset of leukocyte infiltration
that began several weeks after irradiation and reached a peak
at  20 wk after irradiation. Masson’s trichrome staining of
irradiated lungs further showed the development of fibrosis
by progressive collagen deposition after week 12. This fibro-
genesis phase was characterized by development of typical fi-
Figure 5. Histological assessment of lung fibrosis. (A) Photomicro-
graphs of hematoxylin and eosin–stained lung tissue sections from control 
mice, irradiated mice (20 Gy, RT), and mice treated with SU9518 after 
thoracic irradiation (intervention, RT SU9518) at 12, 16, 20, and 24 wk 
after radiation. Bar, 100  m. (B) Masson’s trichrome staining of lung 
sections 12, 16, 20, and 24 wk after irradiation without (RT) or with ad-
ministration of SU9518 (RT SU9518). Examples of focal fibrotic lesions 
(*), areas of “normal” lung (black arrows), and inflammatory cell infiltration 
(L, red) are marked. Scale bar, 100  m. (C) Time course of septal edema 
development in irradiated mice (RT) with maximum edema at 72 h after 
radiation (P   0.05 RT vs. control for each time from 0 h to 4 wk). The 
preventive or interventive administration of SU9518 (SU9518 RT, 
RT SU9518) had significant suppressive effects on edema development, 
except at 72 h after radiation (P   0.05 vs. RT). (D) Septal fibrosis devel-
ops progressively several weeks after radiation (P   0.05 RT vs. control 
for each time point after week 2). Both the SU9518 intervention 
(RT SU9518) and prevention (SU9518 RT) treatment significantly reduced 
the progression of septal fibrosis, as measured by the extent of alveolar wall 
thickness, at all time points after week 2 (P   0.05 vs. RT for each time 
point). However, septal fibrosis was not completely inhibited by the com-
pound (P   0.05 vs. the control after week 2). (E) Quantitative analysis of 
leukocyte numbers at various times after irradiation (20 Gy, RT) reveals 
two peaks. SU9518 before (SU9518 RT) or after (RT SU9518) irradia-
tion did not significantly attenuate the early leukocyte peak (P   0.2). 
Both the preventive (SU9518 RT) and interventional (RT SU9518)
administration of SU9518 significantly inhibited the fibrosis-associated 
second inflammatory response during weeks 2–26 (P   0.05 vs. RT for 
each time point). However, the second fibrosis-associated inflammation 
was not completely inhibited by SU9518 (P   0.05 vs. the control after 
week 2). Bars are mean   SD.JEM VOL. 201, March 21, 2005 931
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broblast foci, with abnormal wound healing/repair leading
to replication of mesenchymal cells, as characterized by fi-
broblast/myofibroblast migration and proliferation and exu-
berant deposition of extracellular matrix in irradiated lungs.
SU9518 treatment markedly reduced collagen deposition,
alveolar wall thickness (P   0.05), and all other histologically
visible signs of fibrosis (Fig. 5, B and D).
At later time points ( 20 wk), the fibroblast foci evolved
and coalesced into more widespread fibrosis with remodel-
ing of the lung architecture (Fig. 5, A and B). Thus, in the
irradiated lungs, the second onset of progressive fibrogenesis-
related infiltration of leukocytes persisted until the morpho-
logically described fibrosis process was completed (after
week 26). SU9518 intervention and prevention significantly
inhibited this fibrosis-associated second inflammatory re-
sponse, as demonstrated by reduced leukocyte counts from
weeks 2–26 (P   0.05 for each time point).
DISCUSSION
Here, we show the pivotal role of PDGF signaling in the
pathogenesis of radiation-induced pulmonary fibrosis. Im-
portantly, our findings suggest that direct inhibition of fibro-
genesis by PDGF RTKIs is an effective strategy to attenuate
lung fibrosis. We found that three distinct inhibitors of
PDGF signaling (Imatinib/Gleevec, SU9518, and SU11657)
markedly attenuated pulmonary fibrosis in a mouse model of
radiation-induced lung fibrosis (C57/Bl6).
We could demonstrate that treatment of irradiated mice
with PDGF RTKIs markedly attenuates the development of
fibroblast foci, the hallmark of pulmonary fibrosis, and the
subsequent remodeling of the lung architecture. The mor-
phological results were in agreement with qualitative and
quantitative high resolution CT scans of mouse lungs, dem-
onstrating that PDGFR inhibition could dramatically atten-
uate the typical radiological features of lung fibrosis induced
by thoracic irradiation.
Interestingly, with respect to the time course of fibrosis
development, we found that PDGF RTKIs were more ef-
fective when administered after thoracic irradiation in an in-
tervention schedule than when giving them before irradia-
tion in a prevention schedule. No antifibrotic therapy has
been clearly shown to prolong survival in patients with lung
fibrosis (1, 6, 7, 9). Therefore, we conclude from our data
that demonstrate a significant survival benefit and reduced
clinical morbidity in PDGF RTKI–treated mice that a ratio-
nale exists for clinical testing of this class of compounds in
patients developing pulmonary fibrosis.
On a cellular level, our coculture data suggest that para-
crine PDGF secretion is an important source of radiation-
induced fibroblast proliferation. Likewise, we found that
radiation induced persistent exaggerated release of all four
PDGF (A–D) isoforms with consequent activation of PDGFR
in fibroblasts both in vitro and in vivo in mice lungs, thus in-
dicating an important role for PDGF signaling in radiation-
induced fibrogenesis and pulmonary fibrosis.
The high antifibrotic efficacy of Imatinib, SU11657, and
SU9518 in our mouse study might be explained in part by
the fact that all RTKIs are potent inhibitors of both
PDGFR-  and PDGFR-  isoforms. Thus, it is conceivable
that PDGF signaling was effectively attenuated through all
stages of the disease, regardless of preferential expression of a
specific PDGF isoform at a given time. The compound
SU9518 exhibits great potency with high selectivity for inhi-
bition of PDGF-induced proliferation relative to FGF- and
EGF-induced proliferation (30). The IC50 values for SU9518
inhibition of PDGF-, FGF-, and EGF-induced BrdU incor-
poration using mouse fibroblasts were 0.053, 4.40, and 9.63
 Mol, respectively. Further, SU9518 exhibited no inhibi-
tion of isolated EGFR kinase using a biochemical assay (30).
However, considering the large number of human kinases
(32), the possibility that the effects might be mediated by in-
hibition of other kinases cannot be completely excluded.
This issue would be applicable to most available small mole-
cule RTKIs, because current kinase inhibitors never exhibit
exquisite selectivity (33–36). Although their effects are not
fully elucidated, some RTKIs have entered clinical applica-
tions. For example, Imatinib is successfully used for (a) the
treatment of chronic myelogenous leukemia with the pri-
mary rationale inhibition of Bcr/Abl kinase; (b) gastrointesti-
nal stromal tumors (inhibition of c-Kit); and (c) malignant
brain tumors, lung cancer, and other solid tumors (inhibition
of PDGFR; references 34 and 37).
To strengthen our concept of PDGF involvement in fi-
brosis, we present data using two other small molecule RT-
KIs (besides SU9518) that are considered PDGFR inhibitors
with different kinase selectivity profiles: Imatinib (Gleevec)
with high activity against three kinases, Bcr/Abl, c-Kit, and
PDGFR-  and PDGFR-  (31, 34, 37, 38), and SU11657, a
multi-targeted inhibitor of class III/V receptor tyrosine ki-
nases with selectivity similar to SU11248 (inhibits PDGFR- 
and PDGFR- , VEGFR-2, flt3, and c-kit), which is cur-
rently investigated in phase I/II clinical cancer trials (34, 39).
Thus, the significant overlap among the three PDGFR in-
hibitors used is PDGFR inhibition. All three inhibitors were
found to reduce lung fibrosis after radiation injury and pro-
longed animal survival. Together with our data on radiation-
induced PDGF expression and phosphorylation of PDGFR
in vitro and in vivo, we suggest that the inhibition of the
PDGFR signaling is the key mechanism behind our func-
tional findings.
In the past, an important assumption was that fibrosis
might be avoided if the inflammatory cascade was inter-
rupted before irreversible tissue injury occurred (6, 7). This
led to initial enthusiasm for corticosteroid and cytotoxic
therapy for IPF. However, it is now accepted that current
antiinflammatory therapies, even in combination with po-
tent immunosuppressives, fail to improve the disease out-
come (1, 6–9). Therefore, acute inflammation is not the only
critical step in development of the fibrotic response (7, 8, 40,
41) and a new hypothesis seems in order (Fig. 6). We foundATTENUATION OF LUNG FIBROSIS | Abdollahi et al. 932
that although the acute inflammatory response induced by
radiation injury was not completely abrogated, inhibition of
PDGF signaling attenuated the onset and development of
lung fibrosis. The fibrotic tissue alteration was accompanied
by a second chronic inflammatory response that was dramat-
ically attenuated by PDGF RTKIs. Accordingly, the acute
radiation-induced expression of PDGF isoforms was mildly
affected by the PDGF RTK, whereas the fibrosis-related
PDGF expression at later time points (week 20) was signifi-
cantly attenuated. Thus, the potent direct inhibition of fib-
rogenesis consisting of stromal cell migration, proliferation,
and extracellular matrix deposition seems to be the principal
target of PDGF RTKIs.
The potential of PDGF inhibition for the treatment of
lung fibrosis is supported by previous data implicating the
PDGF–PDGFR system in IPF-, asbestos-, bleomycin-, and
radiation-induced lung fibrosis (20, 27, 42–46) as well as fi-
brosis in other organs such as the kidneys, liver, skin, and heart
(47–50). Administration of the PDGF RTK AG1296, a tyro-
phostin analogue, has been shown to reduce pulmonary fibro-
sis in a rat model of metal-induced lung injury (35). Imatinib
has been shown to ameliorate chronic allograft nephropathy in
rats (36), to attenuate bone marrow fibrosis in patients with
chronic myelogenous leukemia (38), and very recently to
inhibit TGF- –dependent bleomycin-mediated fibrosis (51).
An advantage of our radiation-induced lung fibrosis
model might be that the development of lung fibrosis occurs
relatively slowly up to 26 wk after irradiation, thus resem-
bling the time course in humans. In other lung fibrosis
models, the fibrotic end-stage is typically reached by 4 wk
or earlier after the instillation of, e.g., bleomycin or vana-
dium pentoxid (35, 51). In patients with advanced lung can-
cer, radiotherapy is considered the mainstay of therapy.
However, therapy-related normal tissue radiosensitivity that
leads to pulmonary fibrosis limits the delivery of effective ra-
diation doses for a curative treatment of lung cancer patients.
Thus, the ability to reduce normal tissue complication sus-
ceptibility could allow oncologists to increase the radiation
dose to be given, which in turn could enhance cancer cure
rates. On the other hand, because PDGF RTKI are also be-
ing investigated as cancer drugs (25, 31), a twofold rationale
for their use in radiation oncology might unfold.
Taken together, we demonstrate that direct interven-
tion in fibrogenesis using PDGF RTKIs might be a useful
approach to the therapy of radiation-induced lung fibrosis.
However, it is unlikely that single pathway inhibition can
completely prevent lung fibrosis in humans, considering the
intricate genetic networking (52, 53). Nevertheless the
PDGF RTKIs that are undergoing clinical studies or are
approved for certain oncological indications (e.g., SU11248
Figure 6. Model of fibrosis development integrating our findings. 
The data suggest that a fibrosis-generating stimulus such as ionizing radi-
ation initiates an inflammatory response consisting of leukocyte infiltration 
and the release of proinflammatory/profibrotic cytokines such as PDGF. 
This acute tissue response initiates a constitutive chronic stimulation and 
activation of the fibroblasts by PDGF, with subsequent proliferation and 
extracellular matrix deposition. PDGF RTKIs inhibits fibrogenesis induced 
by the release of PDGF from injured endothelial cells, epithelial cells, and 
infiltrated macrophages.JEM VOL. 201, March 21, 2005 933
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or Gleevec [STI571/Imatinib]; reference 34) may have ap-
propriate potency, selectivity, and safety profiles for the
treatment of fibrosis-related diseases. This could be of ben-
efit for patients with idiopathic forms of fibrosis and also for
lung cancer patients to enhance the therapeutic efficacy by
simultaneously reducing the radiation-induced undesired
side effects.
MATERIALS AND METHODS
Reagents and cell culture. Primary isolated human dermal fibroblasts,
HUVECs (Promocell), HLMVECs (Clonetics/ Cambrex Bio Science), and
human non-small cell lung cancer cell line A549 (Tumorbank DKFZ) were
cultured as described previously (25, 54).
An in vitro coculture system was used as described previously with mi-
nor modifications (25, 54). In brief, endothelial and A549 cells were grown
in 24-well plates and irradiated with 10 Gy. Separately, collagen I–coated
transwell inserts (Becton Dickinson) were plated with 20,000 fibroblasts and
preincubated with 5  M SU9518 for 1 h. After irradiation of A549 cells and
endothelial cells, the transwells containing the fibroblasts were transferred
into the 24-well plates and incubated for 72 h before counting the fibroblasts.
Experimental protocol and animal model. All animal procedures
were approved by institutional and governmental authorities. Fibrosis-
prone mice (8-wk-old female C57BL/6J mice with an approximate body
weight of 20 g; Charles River Laboratories) were used. For thoracic irradia-
tion, mice were anesthetized by intraperitoneal application of 0.2 mg/kg
Domitor (Pfizer) and 100 mg/kg ketamin 10% (Parke-Davis). Cobalt-60  
radiation (Siemens Gammatron S) was administered as single dose (20 or 40
Gy as indicated) to the entire thorax (0.441 Gy/min; source surface distance
of 0.7 m) using one standing field anterior-posterior. Other organs, above
and beyond the thorax, were shielded. Animals were supplied with diet and
water ad libitum. The first set of animal experiments was performed to ana-
lyze the effects of the PDGF RTKI SU9518 in radiation-induced lung fi-
brosis. The second set of experiments was performed to independently con-
firm the results using Imatinib and SU11657, two other PDGFR RTKIs
with otherwise different kinase inhibitory spectrum.
Treatment with RTKI. PDGF RTKIs were synthesized at SUGEN Inc.
SU9518 was administered s.c. at 100 mg/kg (in 0.5% carboxymethylcellulose
sodium USP, 0.9% sodium chloride, 0.4% polysorbate 80, 0.9% benzyl alco-
hol, and 4 ml/kg deionized water) twice weekly until the end of the observa-
tion period. To achieve a clinically relevant dose (31), Imatinib and SU11657
were formulated in standard mouse chow at 0.5 (Imatinib) and 0.0125 mg/g
(SU11657), respectively. SU9518 is a selective and potent inhibitor of cellular
PDGFR- , PDGFR- , and PDGF receptor–induced cell proliferation and
has demonstrated activity in preventing arterial stenosis in a rat model (30).
Imatinib (Gleevec) has high activity against three kinases: Bcr/Abl, c-Kit, and
PDGFR-  and PDGFR-  (31, 34, 37, 38). SU11657 has been shown to in-
hibit VEGFR-1, VEGFR-2, and PDGFR-  and PDGFR-  (34, 39). Thus,
among known kinases tested, Imatinib/Gleevec, SU11657, and SU9518
overlap in their inhibition of PDGFR-  and PDGFR- .
Real-time quantitative RT-PCR. Expression levels of RNA transcripts
were quantitated by real-time PCR. Total RNA from A549 cells, HLM-
VECs, and frozen lung tissues (mouse) were isolated using RNeasy Kit
(QIAGEN). RNA quality was ensured by lab-on chip technology according
to the manufacturer’s instructions (2100 bio-analyzer in combination with
the RNA 6000 Lab Chip kit; Agilent Technologies) and spectrophotometric
analysis. The RNA only was used with a 28S/18S ribosomal RNA ratio of
2.0 ( 0.3). SYBR Green assay and the ABI Prism 7900HT Sequence De-
tection System (Applied Biosystems) were used for the real-time quantitation
of the RNA. A consensus sequence, derived from Locus Link/refseq database
(NCBI, http://www.ncbi.nlm.nih.gov/LocusLink; accession nos: mPDGF-A:
NM_008808; mPDGF-B: NM_011057; mPDGF-C: NM_019971;
mPDGF-D: NM_027924; hPDGF-A: NM_002607; hPDGF-B: NM_002608;
hPDGF-C: NM_016205; and hPDGF-D: NM_025208), was used to de-
sign the forward and reverse primers to the sequences using ABI’s Primer
Express software (Cytomyx). The primers were as follows: mPDGF-A:
forward 5 -GGCTGGCTCGAAGTCAGATC-3  and reverse 5 -CCTC-
AGCCCCTACGGAGTCT-3 ; mPDGF-B: forward 5 -AAGCTCGGG-
TGACCATTCG-3  and reverse 5 -ACTTTCGGTGCTTGCCTTTG-3 ;
mPDGF-C: forward 5 -CTCGGGCTGAGTCCAACCT-3  and reverse
5 -TTGCACTCCGTTCTGTTCCTT-3 ; mPDGF-D: forward 5 -CCA-
AGGAACCTGCTTCTGACA-3  and reverse 5 -TCCGAATTGATGG-
TCAAAGGA-3 ; hPDGF-A: forward 5 -GTGGCCAAGGTGGAATA-
CGT-3  and reverse 5 -CGCACTCCAAATGCTCCTCTA-3 ; hPDGF-B:
forward 5 -AGATCGAGATTGTGCGGAAGA-3  and reverse 5 -
GCTGCCACTGTCTCACACTTG-3 ; hPDGF-C: forward 5 -GGACT-
CAGGCGGAATCCAA-3  and reverse 5 -CTGAGGATCTTGTACTC-
CGTTCTG-3 ; and hPDGF-D: forward 5 -CAATGATGATGCCAAG-
CGTTA-3  and reverse 5 -TGGCCAACTTCAGCTCTTCTC-3 . After
RNA isolation, contaminating genomic DNA was removed by DNase 1
treatment (DNA-free; Ambion). First strand cDNA was reverse transcribed
from total RNA using the cDNA Archive Kit (MultiScribe Reverse Tran-
scriptase; Applied Biosystems) and stored at  20 C until use. Complementary
DNAs were mixed with SYBR Green PCR master mix (Applied Biosystems)
and primers, and real-time PCR was performed. In addition to profiling all
samples for the target sequence, samples were profiled for 18S (ribosomal
RNA) expression as endogenous control. For each single well amplification
reaction, a threshold cycle (CT) was observed in the exponential phase of am-
plification, and the quantitation of relative expression levels was achieved us-
ing standard curves for both the target and endogenous controls. All assays
were performed in triplicate.
Pharmacokinetic analysis. Pharmacokinetic analysis was performed as
described previously (30). In brief, blood samples from mice were obtained
and RTKIs were extracted from the plasma. HPLC/mass spectrometric
analysis was performed.
Lung histology and immunohistochemistry. Histological analysis from
mice tissues was performed systematically at early and later time points after
radiation until 26 wk as described previously (55). In brief, lungs were fixed
by intratracheal instillation of 4% formalin followed by overnight fixation,
embedding in paraffin, sectioning at 5  m, and staining with hematoxylin
and eosin or Masson’s trichrome. The total count of leukocytes, intraalveolar
edema, and septal thickness were determined by morphometric evaluation
(Q 600 Quantimet; Leica).
Immunohistochemistry was performed for PDGFB, PDGFR , and
phopho-PDGFR. In brief, lung sections were deparaffinized and stained
with anti–PDGF-B (no. sc-7878; Santa Cruz Biotechnology, Inc.), anti–
PDGFR-  (no. sc-432; Santa Cruz Biotechnology, Inc.), or anti–phospho-
PDGFR (nos. 3161 and 3391; Cell Signaling Technologies) primary anti-
bodies. Biotin-conjugated goat anti–rabbit IgG second antibody (BA-1000;
Vector Laboratories) was used and the sections were detected with DAB 
reagent (no. K3468; DakoCytomation) after incubation with Elite ABC re-
agent (Vector Laboratories) according to the manufacturer’s instructions.
Control sections were routinely analyzed in other organs including the kid-
ney, skin, muscle, and spleen to investigate potential side effects of RTKIs.
High resolution CT. To obtain an independent qualitative and quantita-
tive measure for lung fibrosis in the mice, we used high resolution CT. CT
is the radiological method of choice for monitoring fibrosis in patients (1, 5, 7).
This radiological method allows noninvasive and repeated measurements in
the same mice in a longitudinal study (55). CT was performed in 10 ran-
domly selected mice from each group every second week during the entire
observation period. CT images were captured on a Somatom Plus 4 Vol-
ume Zoom multi-slice CT scanner (Siemens). 120 kV with 100 mAS were
applied. 0.5-mm thin slices with 0.5-mm inter-slice distance spanned the
complete mouse chest (a total acquisition time of 0.5 s). Multiplanar recon-ATTENUATION OF LUNG FIBROSIS | Abdollahi et al. 934
structions were performed for semiquantitative analysis. HU of section
slides from the upper and lower lung region were determined. Eight regions
of interest were defined in the following areas: the right upper anterior and
posterior regions, the left upper anterior and posterior regions, the right
lower anterior and posterior regions, and the left lower anterior and poste-
rior regions. Total arithmetic means   SD of the HU were calculated. For
the Imatinib/Gleevec and SU11657 confirmation study, a different CT
scanner was used (Aquilion 32; Toshiba).
PDGFR phosphorylation in lungs. After protein isolation and homog-
enization of the frozen mouse lung, the protein content was determined,
and equal amounts of protein were used in each IP. The lysate was incu-
bated with anti-PDGFR  antibody (no. 06-498; Upstate Biotechnology)
and protein A agarose beads overnight at 4 C. The beads were collected by
centrifugation and washed. The protein on the beads was dissolved in SDS-
PAGE buffer, fractionated on a 12% gel, and transferred to a nitrocellulose
membrane. After blocking, the blot was probed for phosphotyrosine with
PY99 antibody (no. sc-7020; Santa Cruz Biotechnology, Inc.) and visual-
ized with ECL reagents (Pierce Chemical Co.). The blots were then
stripped and reprobed for total PDGFR  with anti-PDGFR  antibody
(no. sc-432; Santa Cruz Biotechnology).
Statistics. Mouse survival curves after thoracic irradiation and RTKI treat-
ments were calculated with the Kaplan-Meier method and compared using
the log-rank test. Other quantitative data are given as mean values   SD or
as indicated. For analysis of differences between the groups, ANOVA fol-
lowed by the appropriate post hoc test for individual comparisons between
the groups was performed. All tests were two-tailed. P   0.05 was consid-
ered statistically significant.
Online supplemental material. Additional data on longitudinal histo-
logical and CT assessments are available at http://www.jem.org/cgi/
content/full/jem.20041393/DC1.
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